Pharma's Q1 to benefit from higher prices

Most major U.S. drugmakers' first-quarter results are likely to benefit from higher prices as the industry continues efforts to bolster product pipelines ahead of the expiration of patent protection on some key drugs over the next few years, Dow Jones says. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.